According to DCG (I) file No. 4-01/2013-DC (Misc 13-PSC) dated 15 Jan 2013, In respect of FDC Falling under definition of “New Drug” licensed by state licensing Authorities before 1.10.12, without the permission of DCG (I), it has been decided that the DCG (I) will ask all the state drug controllers to ask the concerned manufacturers to prove the Safety and Efficacy of such FDCs before CDSCO within a period of 18 months, failing which such FDCs will be considered for being prohibited for manufacture and marketing in the country.
The new FDCs, if any, licensed by the state licensing authorities after 01.10.12 without approval of DCG(I), the same will be considered for being prohibited for manufacture and marketing in the country.
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..